

# CITATION REPORT

List of articles citing

**Consensus document: therapeutic monitoring of tacrolimus (FK-506)**

**DOI: 10.1097/00007691-199512000-00011**  
**Therapeutic Drug Monitoring, 1995, 17, 606-14.**

**Source:** <https://exaly.com/paper-pdf/25663412/citation-report.pdf>

**Version:** 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
244	Clinical pharmacokinetics of tacrolimus. <b>1995</b> , 29, 404-30		553
243	The use of therapeutic drug monitoring to optimise immunosuppressive therapy. <b>1996</b> , 30, 107-40		50
242	Toxic effects of immunosuppressive drugs: mechanisms and strategies for controlling them. <b>1996</b> , 42, 1316-1321		55
241	Comparison of binding characteristics of four rapamycin metabolites to the 14 and 52 kDa immunophilins with their pharmacologic activity measured by the mixed-lymphocyte culture assay. <b>1996</b> , 29, 309-13		14
240	Receptor assays in the clinical laboratory. <b>1996</b> , 29, 439-44		8
239	Relationship of whole-blood FK506 concentrations to rejection and toxicity in liver and kidney transplants. <b>1996</b> , 6, 411-24		17
238	Monitoring new immunosuppressive agents. Are the methods adequate?. <b>1997</b> , 14, 5-15		13
237	Drugs acting on the immune system. <b>1997</b> , 20, 326-362		1
236	Review of immunosuppression for lung transplantation. Novel drugs, new uses for conventional immunosuppressants, and alternative strategies. <b>1997</b> , 18, 353-66		28
235	Improved Therapeutic Drug Monitoring of Tacrolimus (FK506) by Tandem Mass Spectrometry. <b>1997</b> , 43, 2189-2190		30
234	Optimization of Nonisotopic PCR Single-Strand Conformation Polymorphism Analysis. <b>1997</b> , 43, 2190-2192		3
233	Comparison of old and new IMX assays for monitoring of tacrolimus levels. <b>1997</b> , 10, 409-10		7
232	An HPLC/MS/MS assay for tacrolimus in patient blood samples. Correlation with results of an ELISA assay. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , <b>1997</b> , 16, 7-13	3.5	38
231	Role of immunophilins in therapeutic drug monitoring of immunosuppressive drugs. <b>1998</b> , 31, 381-4		11
230	Therapeutic drug monitoring of cyclosporine and tacrolimus. Update on Lake Louise Consensus Conference on cyclosporin and tacrolimus. <b>1998</b> , 31, 309-16		114
229	Tacrolimus metabolite cross-reactivity in different tacrolimus assays. <b>1998</b> , 31, 613-7		54
228	Tacrolimus pharmacokinetics in BMT patients. <b>1998</b> , 21, 23-8		35

227	Pharmacokinetics of tacrolimus and cyclosporine in short-bowel syndrome. <b>1998</b> , 4, 432-4		15
226	Development of a high-performance liquid chromatographic-electrospray mass spectrometric assay for the specific and sensitive quantification of the novel immunosuppressive macrolide 40-O-(2-hydroxyethyl)rapamycin. <b>1998</b> , 720, 179-87		27
225	Suivi thérapeutique des immunosuppresseurs: données actuelles. <b>1998</b> , 1998, 75-82		
224	Collaboration between pharmacy and laboratory: defining total allowable error limits for therapeutically monitored drugs. <i>Annals of Pharmacotherapy</i> , <b>1998</b> , 32, 170-5	2.9	4
223	Renal endothelin in FK506-induced nephrotoxicity in spontaneously hypertensive rats. <b>1998</b> , 76, 39-49		14
222	Modified pentamer formation assay for measurement of tacrolimus and its active metabolites: comparison with liquid chromatography tandem mass spectrometry and microparticle enzyme-linked immunoassay (MEIA-II). <b>1998</b> , 44, 2516-2523		28
221	Prospective investigations of concentration clinical response for immunosuppressive drugs provide the scientific basis for therapeutic drug monitoring. <b>1998</b> , 44, 381-387		29
220	Comparison of the Abbott IMx Tacrolimus I and Tacrolimus II Assays. <b>1998</b> , 44, 1783-1785		5
219	Evaluation of the tacrolimus II microparticle enzyme immunoassay (MEIA II) in liver and renal transplant recipients. <b>1998</b> , 44, 1942-1946		54
218	Analytical Validation of the PRO-Trac II ELISA for the Determination of Tacrolimus (FK506) in Whole Blood. <b>1999</b> , 45, 1449-1458		21
217	Bioequivalence of 1 and 5 mg tacrolimus capsules using a replicate study design. <b>1999</b> , 39, 1032-7		15
216	Tacrolimus whole blood concentrations correlate closely to side-effects in renal transplant recipients. <b>1999</b> , 48, 445-8		116
215	Therapeutic drug monitoring of immunosuppressant drugs. <b>1999</b> , 47, 339-50		53
214	Optimum use of tacrolimus in the prophylaxis of graft versus host disease. <b>1999</b> , 11, 343-58		4
213	Dose linearity after oral administration of tacrolimus 1-mg capsules at doses of 3, 7, and 10 mg. <b>1999</b> , 21, 2058-64		14
212	Current opinions on therapeutic drug monitoring of immunosuppressive drugs. <b>1999</b> , 21, 1632-52; discussion 1631		89
211	Low systemic exposure to tacrolimus correlates with acute rejection. <b>1999</b> , 31, 296-8		135
210	Tacrolimus (FK 506). <b>1999</b> , 83, 179-89; quiz 189-90		39

209	Maintenance immunosuppression: new agents and persistent dilemmas. <b>2000</b> , 7, 95-116	23
208	Therapeutic drug monitoring in solid-organ transplant recipients. <b>2000</b> , 5, 330-335	3
207	Coadministration of tacrolimus and mycophenolate mofetil in stable kidney transplant patients: pharmacokinetics and tolerability. <b>2000</b> , 40, 527-32	27
206	Evaluation of microparticle enzyme immunoassay against HPLC-mass spectrometry for the determination of whole-blood tacrolimus in heart- and lung-transplant recipients. <b>2000</b> , 33, 557-62	15
205	Minor immunophilin binding of tacrolimus and sirolimus metabolites. <b>2000</b> , 33, 1-6	8
204	Biochemical characterization of the minor immunophilins. <b>2000</b> , 33, 81-7	3
203	Automated, fast and sensitive quantification of drugs in blood by liquid chromatography-mass spectrometry with on-line extraction: immunosuppressants. <b>2000</b> , 748, 41-53	143
202	Systemic and intratubular effects of cyclosporin-A and tacrolimus on the rat kidney. <b>2000</b> , 399, 215-21	1
201	Proficiency-testing issues relating to sirolimus. <b>2000</b> , 22 Suppl B, B122-132	19
200	Drug concentration monitoring of immunosuppressive agents: focus on tacrolimus, mycophenolate mofetil and sirolimus. <b>2000</b> , 14, 355-69	15
199	Tacrolimus: a further update of its pharmacology and therapeutic use in the management of organ transplantation. <b>2000</b> , 59, 323-89	202
198	Covariate effects on the apparent clearance of tacrolimus in paediatric liver transplant patients undergoing conversion therapy. <b>2001</b> , 40, 63-71	37
197	Comparative clinical pharmacokinetics of tacrolimus in paediatric and adult patients. <b>2001</b> , 40, 283-95	102
196	Therapeutic drug monitoring for immunosuppressants. <b>2001</b> , 313, 241-53	80
195	Pharmacokinetics of tacrolimus during the early phase after heart transplantation. <b>2001</b> , 33, 2386-9	12
194	FK 506 dose in transplantation: from theory to practice. <b>2001</b> , 33, 2594-7	5
193	Therapeutic drug monitoring [Is it important for newer immunosuppressive agents?]. <b>2001</b> , 17, 8-12	0
192	Comparative tacrolimus pharmacokinetics: normal versus mildly hepatically impaired subjects. <b>2001</b> , 41, 628-35	30

191	Clinical utility of monitoring tacrolimus blood concentrations in liver transplant patients. <b>2001</b> , 41, 542-51		118
190	Effect of low- and high-fat meals on tacrolimus absorption following 5 mg single oral doses to healthy human subjects. <b>2001</b> , 41, 176-82		89
189	Comparison of ELISA method versus MEIA method for daily practice in the therapeutic monitoring of tacrolimus. <b>2001</b> , 16, 2246-9		13
188	Therapeutic drug monitoring of tacrolimus in pediatric liver transplant patients. <b>2001</b> , 5, 119-24		17
187	Quantitative relationship between myocardial concentration of tacrolimus and QT prolongation in guinea pigs: pharmacokinetic/pharmacodynamic model incorporating a site of adverse effect. <b>2001</b> , 28, 533-54		44
186	The pharmacokinetics and metabolic disposition of tacrolimus: a comparison across ethnic groups. <b>2001</b> , 69, 24-31		153
185	New developments in the immunosuppressive drug monitoring of cyclosporine, tacrolimus, and azathioprine. <b>2001</b> , 34, 9-16		125
184	Immunosuppressant drugs ¶the role of therapeutic drug monitoring. <b>2001</b> , 52, 61-73		1
183	Validation of methods to study the distribution and protein binding of tacrolimus in human blood. <b>2001</b> , 46, 27-35		66
182	Immunosuppressant drugs ¶the role of therapeutic drug monitoring. <b>2001</b> , 52, 61-73		32
181	Principles and Practice of Monitoring Immunosuppressive Drugs/Grundsätze und Praxis beim Monitoring von Immunsuppressiva. <b>2002</b> , 26, 27-36		1
180	International Federation of Clinical Chemistry/International Association of Therapeutic Drug Monitoring and Clinical Toxicology working group on immunosuppressive drug monitoring. <i>Therapeutic Drug Monitoring</i> , <b>2002</b> , 24, 59-67	3.2	70
179	Comparison of an ELISA and an LC/MS/MS method for measuring tacrolimus concentrations and making dosage decisions in transplant recipients. <i>Therapeutic Drug Monitoring</i> , <b>2002</b> , 24, 607-15	3.2	37
178	Randomized controlled trial of oral itraconazole solution versus intravenous/oral fluconazole for prevention of fungal infections in liver transplant recipients. <i>Transplantation</i> , <b>2002</b> , 74, 688-95	1.8	77
177	Drug interactions with tacrolimus. <b>2002</b> , 25, 707-12		87
176	Immunosuppressive therapy for paediatric transplant patients: pharmacokinetic considerations. <b>2002</b> , 41, 115-35		66
175	Mechanisms of clinically relevant drug interactions associated with tacrolimus. <b>2002</b> , 41, 813-51		217
174	Evaluation of the new EMIT enzyme immunoassay for the determination of whole-blood tacrolimus concentrations in kidney, heart, and liver transplant recipients. <b>2002</b> , 34, 2988-90		29

173	Principles and Practice of Monitoring Immunosuppressive Drugs. <b>2002</b> , 26, 27-36		3
172	Daclizumab induction/tacrolimus sparing: a randomized prospective trial in renal transplantation. <i>Clinical Transplantation</i> , <b>2002</b> , 16 Suppl 7, 30-3	3.8	9
171	IMx tacrolimus II assay: is it reliable at low blood concentrations? A comparison with tandem MS/MS. <b>2002</b> , 35, 389-92		31
170	Population pharmacokinetics of tacrolimus in adult kidney transplant recipients. <b>2002</b> , 72, 660-9		110
169	Genetic polymorphisms of the CYP3A4, CYP3A5, and MDR-1 genes and pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimus. <b>2003</b> , 74, 245-54		501
168	Toward better outcomes with tacrolimus therapy: population pharmacokinetics and individualized dosage prediction in adult liver transplantation. <b>2003</b> , 9, 130-7		56
167	Tacrolimus dosing in pediatric heart transplant patients is related to CYP3A5 and MDR1 gene polymorphisms. <b>2003</b> , 3, 477-83		206
166	Liquid chromatography/mass spectrometry for therapeutic drug monitoring of immunosuppressants. <b>2003</b> , 492, 133-145		29
165	Immune cell function testing: an adjunct to therapeutic drug monitoring in transplant patient management. <i>Clinical Transplantation</i> , <b>2003</b> , 17, 77-88	3.8	206
164	Milk transfer and neonatal safety of tacrolimus. <i>Annals of Pharmacotherapy</i> , <b>2003</b> , 37, 815-8	2.9	78
163	Evaluation of the Dade Behring Syva EMIT 2000 tacrolimus assay on the Bayer Advia 1650. <b>2003</b> , 40, 697-700		8
162	Pharmacokinetics of tacrolimus after multidose oral administration and efficacy in the prevention of allograft rejection in cats with renal transplants. <b>2003</b> , 64, 926-34		5
161	Bayesian forecasting and prediction of tacrolimus concentrations in pediatric liver and adult renal transplant recipients. <i>Therapeutic Drug Monitoring</i> , <b>2003</b> , 25, 158-66	3.2	15
160	A pharmacodynamic investigation of tacrolimus in pediatric liver transplantation. <b>2004</b> , 10, 506-12		24
159	Liquid chromatography-negative ion electrospray tandem mass spectrometry method for the quantification of tacrolimus in human plasma and its bioanalytical applications. <b>2004</b> , 805, 13-20		29
158	Simultaneous determination of four immunosuppressants by means of high speed and robust on-line solid phase extraction-high performance liquid chromatography-tandem mass spectrometry. <b>2004</b> , 805, 215-22		101
157	Population pharmacokinetics of cyclosporine in kidney and heart transplant recipients and the influence of ethnicity and genetic polymorphisms in the MDR-1, CYP3A4, and CYP3A5 genes. <b>2004</b> , 76, 545-56		128
156	Clinical monitoring of tacrolimus after liver transplantation using pentamer formation assay and microparticle enzyme immunoassay. <b>2004</b> , 5, 17-22		9

155	Genetic variability in CYP3A5 and its possible consequences. <b>2004</b> , 5, 243-72		237
154	Monitoring immunosuppressive drugs. <i>Handbook of Analytical Separations</i> , <b>2004</b> , 273-296	0.7	1
153	Clinical pharmacokinetics and pharmacodynamics of tacrolimus in solid organ transplantation. <b>2004</b> , 43, 623-53		562
152	Rapid simultaneous quantification of immunosuppressants in transplant patients by turbulent flow chromatography combined with tandem mass spectrometry. <b>2004</b> , 346, 181-90		106
151	Effect of hematocrit on pharmacokinetics of tacrolimus in adult living donor liver transplant recipients. <b>2004</b> , 36, 1506-11		32
150	Sampling times for monitoring tacrolimus in stable adult liver transplant recipients. <i>Therapeutic Drug Monitoring</i> , <b>2004</b> , 26, 593-9	3.2	18
149	Evaluation of a limited sampling strategy to estimate area under the curve of tacrolimus in adult renal transplant patients. <i>Therapeutic Drug Monitoring</i> , <b>2005</b> , 27, 431-4	3.2	35
148	Long-term oral tacrolimus therapy in refractory to infliximab fistulizing Crohn's disease: a pilot study. <b>2005</b> , 11, 8-15		64
147	Therapeutic Drug Monitoring of Tacrolimus. <b>2005</b> , 7, 57-58		1
146	Measurement of Whole Blood Tacrolimus Level by High Performance Liquid Chromatography Tandem Mass Spectrometry in Renal Transplant Recipients [A Single Center Perspective]. <b>2005</b> , 7, 65-69		1
145	Intraindividual and interindividual variations in the pharmacokinetics of mycophenolic acid in liver transplant patients. <b>2005</b> , 45, 34-41		65
144	Clinical Immunosuppression using the Calcineurin-Inhibitors Cyclosporin and Tacrolimus. <b>2005</b> , 321-359		7
143	Tacrolimus monitoring in renal transplantation: a comparison between high-performance liquid chromatography and immunoassay. <b>2005</b> , 37, 1733-5		9
142	Pharmacokinetic considerations relating to tacrolimus dosing in the elderly. <b>2005</b> , 22, 541-57		44
141	Inhibitors of Protein Kinases and Protein Phosphates. <b>2005</b> ,		1
140	Therapeutic drug monitoring and pharmacogenetic tests as tools in pharmacovigilance. <b>2006</b> , 29, 735-68		64
139	Population pharmacokinetics of tacrolimus in whole blood and plasma in asian liver transplant patients. <b>2006</b> , 45, 59-75		46
138	Estimation of minimum whole-blood tacrolimus concentration for therapeutic drug monitoring with plasma prednisolone concentration: A retrospective cohort study in Japanese kidney transplant recipients. <b>2006</b> , 67, 103-17		2

137	Clinical outcomes of renal transplantation using liquid chromatographic monitoring of tacrolimus. <i>Therapeutic Drug Monitoring</i> , <b>2006</b> , 28, 269-73	3.2	4
136	Is microparticle enzyme-linked immunoassay (MEIA) reliable for use in tacrolimus TDM? Comparison of MEIA to liquid chromatography with mass spectrometric detection using longitudinal trough samples from transplant recipients. <i>Therapeutic Drug Monitoring</i> , <b>2006</b> , 28, 491-504	3.2	35
135	Significantly elevated systemic levels after occlusive application of topical tacrolimus in atopic dermatitis. <b>2006</b> , 212, 260-1		5
134	Tandem-Massenspektrometrie in der therapeutischen Arzneimittelspiegel-Bestimmung: Praxis und Tücken der Anwendung / Tandem mass spectrometry in drug monitoring: experience and pitfalls in application. <b>2006</b> , 30, 428-437		
133	Effect of CYP3A5 polymorphism on tacrolimus metabolic clearance in vitro. <b>2006</b> , 34, 836-47		212
132	Analysis of factors influencing tacrolimus levels and immunoassay bias in renal transplantation. <b>2007</b> , 47, 1035-42		7
131	Validation of a liquid chromatography-mass spectrometric assay for tacrolimus in liver biopsies after hepatic transplantation: correlation with histopathologic staging of rejection. <i>Therapeutic Drug Monitoring</i> , <b>2007</b> , 29, 340-8	3.2	43
130	Tacrolimus in diabetic kidney transplant recipients: pharmacokinetics and application of a limited sampling strategy. <i>Therapeutic Drug Monitoring</i> , <b>2007</b> , 29, 391-8	3.2	20
129	Preliminary evaluation of the new TACR flex method versus MEIA method in the therapeutic monitoring of tacrolimus in organ transplantation. <b>2007</b> , 39, 2008-9		10
128	Effect of highly active antiretroviral therapy on tacrolimus pharmacokinetics in hepatitis C virus and HIV co-infected liver transplant recipients in the ANRS HC-08 study. <b>2007</b> , 46, 941-52		48
127	Validation d'une nouvelle méthode de dosage du tacrolimus en vue de son adaptation posologique: comparaison des résultats sur automate RXL Dimension avec ceux obtenus sur Cobas-Mira. <b>2007</b> , 2007, 79-82		
126	Influence of the CYP3A5 genotype on tacrolimus pharmacokinetics and pharmacodynamics in young kidney transplant recipients. <b>2007</b> , 11, 296-300		52
125	Circadian and time-dependent variability in tacrolimus pharmacokinetics. <b>2007</b> , 21, 191-7		39
124	Determination of tacrolimus in rabbit aqueous humor by liquid chromatography-electrospray ionization tandem mass spectrometry. <b>2008</b> , 868, 34-41		9
123	Quantification of cyclosporine and tacrolimus in whole blood. Comparison of liquid chromatography-electrospray mass spectrometry with the enzyme multiplied immunoassay technique. <b>2008</b> , 41, 910-3		36
122	Effect of tacrolimus on activity and expression of P-glycoprotein and ATP-binding cassette transporter A5 (ABCA5) proteins in hematoencephalic barrier cells. <b>2008</b> , 31, 1911-6		11
121	Limited sampling strategy for simultaneous estimation of the area under the concentration-time curve of tacrolimus and mycophenolic acid in adult renal transplant recipients. <i>Therapeutic Drug Monitoring</i> , <b>2008</b> , 30, 52-9	3.2	40
120	[Performance evaluation of affinity column mediated immunometric assay for tacrolimus]. <b>2009</b> , 29, 415-22		6

119	Study of the effect of Wuzhi tablet ( <i>Schisandra sphenanthera</i> extract) on tacrolimus tissue distribution in rat by liquid chromatography tandem mass spectrometry method. <b>2010</b> , 24, 399-405		31
118	Analytical performance characteristics of the Abbott Architect i2000 Tacrolimus assay; comparisons with liquid chromatography-tandem mass spectrometry (LC-MS/MS) and Abbott IMx methods. <b>2009</b> , 410, 25-30		24
117	Interindividual variation of maximal blood levels of tacrolimus after its oral administration in hematopoietic cell transplant recipients. <b>2009</b> , 41, 1831-3		3
116	Preparation of 0.05% FK506 suspension eyedrops and its pharmacokinetics after topical ocular administration. <b>2009</b> , 25, 345-50		25
115	Opportunities to optimize tacrolimus therapy in solid organ transplantation: report of the European consensus conference. <i>Therapeutic Drug Monitoring</i> , <b>2009</b> , 31, 139-52	3.2	347
114	Early phase limited sampling strategy characterizing tacrolimus and mycophenolic acid pharmacokinetics adapted to the maintenance phase of renal transplant patients. <i>Therapeutic Drug Monitoring</i> , <b>2009</b> , 31, 467-74	3.2	25
113	Validation of a liquid chromatography-mass spectrometric assay for tacrolimus in peripheral blood mononuclear cells. <i>Therapeutic Drug Monitoring</i> , <b>2009</b> , 31, 178-86	3.2	46
112	Mechanistic understanding of the different effects of Wuzhi Tablet ( <i>Schisandra sphenanthera</i> extract) on the absorption and first-pass intestinal and hepatic metabolism of Tacrolimus (FK506). <b>2010</b> , 389, 114-21		68
111	Multi-center evaluation of a commercial Kit for tacrolimus determination by LC/MS/MS. <b>2010</b> , 43, 910-20		30
110	CYP3A5 and ABCB1 polymorphisms influence tacrolimus concentrations in peripheral blood mononuclear cells after renal transplantation. <b>2010</b> , 11, 703-14		80
109	Benefit of immune monitoring in heart transplant patients using ATP production in activated lymphocytes. <b>2010</b> , 29, 504-8		72
108	Performance evaluation of the new ADVIA Centaur system cyclosporine assay (single-step extraction). <b>2010</b> , 411, 806-11		11
107	Comparison of the affinity column-mediated immunoassay and microparticle enzyme immunoassay methods as a tacrolimus concentration assay in the early period after liver transplantation. <b>2010</b> , 42, 4137-40		5
106	Analytical performance of the Abbott Architect i2000 tacrolimus assay in Chinese patients after renal transplantation. <b>2010</b> , 42, 4534-7		2
105	Difference in blood tacrolimus concentration between ACMIA and MEIA in samples with low haematocrit values. <b>2010</b> , 62, 1185-8		10
104	Assessing immunologic function through CD4 T-lymphocyte adenosine triphosphate levels by ImmuKnow assay in Chinese patients following renal transplantation. <b>2011</b> , 43, 2574-8		10
103	The effects of early rapid corticosteroid reduction on cell-mediated immunity in kidney transplant recipients. <b>2011</b> , 24, 127-30		3
102	Clinical Pharmacokinetics of Triple Immunosuppression Scheme in Kidney Transplant (Tacrolimus, Mycophenolate Mofetil and Corticosteroids). <b>2011</b> ,		2

101	Monitoring of mycophenolic acid predose concentrations in the maintenance phase more than one year after renal transplantation. <i>Therapeutic Drug Monitoring</i> , <b>2011</b> , 33, 295-302	3.2	14
100	The impact of conversion from prograf to generic tacrolimus in liver and kidney transplant recipients with stable graft function. <b>2011</b> , 11, 1861-7		58
99	Bioequivalence of two tacrolimus formulations under fasting conditions in healthy male subjects. <b>2011</b> , 33, 1105-19		7
98	Pharmacokinetics for once-daily versus twice-daily tacrolimus formulations in de novo liver transplantation: a randomized, open-label trial. <b>2011</b> , 17, 167-77		47
97	Pharmacokinetics of tacrolimus during pregnancy. <i>Therapeutic Drug Monitoring</i> , <b>2012</b> , 34, 660-70	3.2	73
96	Combinational effect of intestinal and hepatic CYP3A5 genotypes on tacrolimus pharmacokinetics in recipients of living donor liver transplantation. <i>Transplantation</i> , <b>2012</b> , 94, 866-72	1.8	33
95	Optimization of the use of Calcineurin inhibitors in liver transplantation. <b>2012</b> , 26, 85-95		20
94	Development and validation of a sensitive LC-MS/MS method for determination of tacrolimus on dried blood spots. <b>2013</b> , 27, 327-34		23
93	Tacrolimus. <b>2012</b> , 224-240		0
92	Risk factors for acute renal injury in living donor liver transplantation: evaluation of the RIFLE criteria. <b>2013</b> , 26, 842-52		69
91	Comparison between ultra-performance liquid chromatography with tandem mass spectrometry and a chemiluminescence immunoassay in the determination of cyclosporin A and tacrolimus levels in whole blood. <i>Experimental and Therapeutic Medicine</i> , <b>2013</b> , 6, 1535-1539	2.1	18
90	Cytochrome P450 3A4FNx011B as pharmacogenomic predictor of tacrolimus pharmacokinetics and clinical outcome in the liver transplant recipients. <b>2013</b> , 19, 89-95		3
89	Manic-like psychosis associated with elevated trough tacrolimus blood concentrations 17 years after kidney transplant. <b>2013</b> , 2013, 926395		10
88	Clinical Pharmacology and Therapeutic Drug Monitoring of Immunosuppressive Agents. <b>2013</b> ,		0
87	Tacrolimus measurement: building a better immunoassay. <b>2014</b> , 60, 575-6		11
86	Oral ulcerations as a sequela of tacrolimus and mycophenolate mofetil therapy. <b>2014</b> , 118, e175-8		14
85	Performance of the ImmuKnow assay in differentiating infection and acute rejection after kidney transplantation: a meta-analysis. <b>2014</b> , 46, 3343-51		16
84	Inhibitory effect of tacrolimus on progression of joint damage in patients with rheumatoid arthritis. <b>2014</b> , 17, 749-54		7

83	Utility of immune monitoring in heart transplant recipients on everolimus-based immune suppression. <i>Clinical Transplantation</i> , <b>2014</b> , 28, 428-33	3.8	5
82	Rapid and sensitive UPLC-MS-MS determination of tacrolimus in Wistar rats and human blood. <b>2014</b> , 52, 59-67		9
81	Clinical evaluation of the QMS <sup>®</sup> Tacrolimus immunoassay. <b>2014</b> , 431, 270-5		11
80	Effect of Genetic Polymorphism of CYP3A5 and CYP2C19 and Concomitant Use of Voriconazole on Blood Tacrolimus Concentration in Patients Receiving Hematopoietic Stem Cell Transplantation. <i>Therapeutic Drug Monitoring</i> , <b>2015</b> , 37, 581-8	3.2	19
79	Monitoring serial CD4+ T-cell function after liver transplantation can be used to predict hepatocellular carcinoma recurrence. <b>2015</b> , 47, 217-22		4
78	A clinical approach to solving discrepancies in therapeutic drug monitoring results for patients on sirolimus or tacrolimus: Towards personalized medicine, immunosuppression and pharmacogenomics. <b>2015</b> , 450, 15-8		5
77	Label-free quantification of Tacrolimus in biological samples by atomic force microscopy. <b>2015</b> , 884, 90-6		7
76	Erratic tacrolimus exposure, assessed using the standard deviation of trough blood levels, predicts chronic lung allograft dysfunction and survival. <b>2015</b> , 34, 1442-8		27
75	Relationship between mRNA expression levels of CYP3A4, CYP3A5 and SXR in peripheral mononuclear blood cells and aging in young kidney transplant recipients under tacrolimus treatment. <b>2015</b> , 16, 483-91		2
74	Evaluation of the Waters MassTrak LC-MS/MS Assay for Tacrolimus and a Comparison to the Abbott Architect Immunoassay. <i>Therapeutic Drug Monitoring</i> , <b>2016</b> , 38, 300-4	3.2	11
73	Therapeutic Drug Monitoring of Everolimus: A Consensus Report. <i>Therapeutic Drug Monitoring</i> , <b>2016</b> , 38, 143-69	3.2	71
72	Assuring the Proper Analytical Performance of Measurement Procedures for Immunosuppressive Drug Concentrations in Clinical Practice: Recommendations of the International Association of Therapeutic Drug Monitoring and Clinical Toxicology Immunosuppressive Drug Scientific Committee. <i>Therapeutic Drug Monitoring</i> , <b>2016</b> , 38, 170-88	3.2	65
71	Extended-release tacrolimus tablets for preventing organ transplant rejection. <b>2016</b> , 4, 1079-1086		
70	Inter-laboratory Variability of Current Immunoassay Methods for Tacrolimus among Japanese Hospitals. <b>2016</b> , 39, 1331-7		10
69	Correlation of Hematocrit and Tacrolimus Level in Liver Transplant Recipients. <b>2016</b> , 48, 1176-8		13
68	Current methods of the analysis of immunosuppressive agents in clinical materials: A review. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , <b>2016</b> , 127, 207-31	3.5	52
67	Comparing the effect of isotopically labeled or structural analog internal standards on the performance of a LC-MS/MS method to determine ciclosporin A, everolimus, sirolimus and tacrolimus in whole blood. <b>2016</b> , 54, 437-46		12
66	Application of physiologically based pharmacokinetic modeling to predict drug disposition in pregnant populations. <b>2017</b> , 38, 426-438		23

65	Tacrolimus-Associated Dilated Cardiomyopathy in Adult Patient After Orthotopic Liver Transplant. <b>2017</b> , 5, 2324709617706087		6
64	Overweight Kidney Transplant Recipients Are at Risk of Being Overdosed Following Standard Bodyweight-Based Tacrolimus Starting Dose. <b>2017</b> , 3, e129		19
63	Switching Stable Kidney Transplant Recipients to a Generic Tacrolimus Is Feasible and Safe, but It Must Be Monitored. <b>2017</b> , 2017, 5646858		3
62	Pharmacokinetics and Genomics of Immunosuppressive Drugs. <b>2017</b> , 429-443		1
61	A simple and highly sensitive on-line column extraction liquid chromatography-tandem mass spectrometry method for the determination of protein-unbound tacrolimus in human plasma samples. <b>2018</b> , 1547, 45-52		13
60	UPLC-MS/MS assay validation for tacrolimus quantitative determination in peripheral blood T CD4+ and B CD19+ lymphocytes. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , <b>2018</b> , 152, 306-314	3.5	9
59	A comparison of the effects of CYP3A5 polymorphism on tacrolimus blood concentrations measured by 4 immunoassay methods in renal transplant patients. <i>Journal of Clinical Pharmacy and Therapeutics</i> , <b>2018</b> , 43, 181-188	2.2	6
58	A Low Fixed Tacrolimus Starting Dose Is Effective and Safe in Chinese Renal Transplantation Recipients. <b>2018</b> , 23, 300-309		4
57	genotype-based model to predict tacrolimus dosage in the early postoperative period after living donor liver transplantation. <b>2018</b> , 14, 2119-2126		6
56	Treatment-Refractory Mania with Psychosis in a Post-Transplant Patient on Tacrolimus: A Case Report. <b>2018</b> , 16, 47-49		6
55	Population pharmacokinetics of tacrolimus in paediatric systemic lupus erythematosus based on real-world study. <i>Journal of Clinical Pharmacy and Therapeutics</i> , <b>2018</b> , 43, 476-483	2.2	16
54	Clinical Pharmacokinetic and Pharmacodynamic Considerations in the Treatment of Ulcerative Colitis. <b>2019</b> , 58, 15-37		46
53	Tacrolimus in adult hematopoietic stem cell transplantation. <b>2019</b> , 15, 803-811		6
52	Limited sampling strategy to predict the area under the curve of tacrolimus in Mexican renal transplant pediatric patients receiving Prograf or non-innovator formulations. <b>2019</b> , 23, e13595		1
51	Population pharmacokinetics of tacrolimus in pediatric refractory nephrotic syndrome and a summary of other pediatric disease models. <i>Experimental and Therapeutic Medicine</i> , <b>2019</b> , 17, 4023-4031 <sup>2.1</sup>		8
50	Wuzhi capsule and haemoglobin influence tacrolimus elimination in paediatric kidney transplantation patients in a population pharmacokinetics analysis: A retrospective study. <i>Journal of Clinical Pharmacy and Therapeutics</i> , <b>2019</b> , 44, 611-617	2.2	18
49	Therapeutic Drug Monitoring of Tacrolimus-Personalized Therapy: Second Consensus Report. <i>Therapeutic Drug Monitoring</i> , <b>2019</b> , 41, 261-307	3.2	163
48	A population pharmacokinetic model to predict the individual starting dose of tacrolimus in adult renal transplant recipients. <b>2019</b> , 85, 601-615		31

47	Reduced variability in tacrolimus pharmacokinetics following intramuscular injection compared to oral administration in cynomolgus monkeys: Investigating optimal dosing regimens. <b>2019</b> , 139, 65-71		1
46	Population pharmacokinetics and dosing regimen optimization of tacrolimus in Chinese pediatric hematopoietic stem cell transplantation patients. <b>2020</b> , 50, 178-185		14
45	Pharmacogenomics analysis in Chinese pediatric liver transplantation patients with renal toxicity induced by tacrolimus. <b>2020</b> , 50, 488-493		3
44	Assessing immunosuppressive drug concentrations in clinical practice. <i>Handbook of Analytical Separations</i> , <b>2020</b> , 7, 277-290	0.7	
43	Initial dose optimization of tacrolimus for children with systemic lupus erythematosus based on the CYP3A5 polymorphism and coadministration with Wuzhi capsule. <i>Journal of Clinical Pharmacy and Therapeutics</i> , <b>2020</b> , 45, 309-317	2.2	6
42	Clinical and safety outcomes of conversion original tacrolimus to generic tacrolimus in Turkish kidney transplant recipients. <i>Transplantation Reports</i> , <b>2020</b> , 5, 100056	0.1	
41	Monitoring cell-mediated immunity during immunosuppression reduction in heart transplant recipients with severe systemic infections. <i>Clinical Transplantation</i> , <b>2020</b> , 34, e13809	3.8	3
40	Body weight-based initial dosing of tacrolimus in renal transplantation: Is this an ideal approach?. <i>Journal of Renal Care</i> , <b>2021</b> , 47, 51-57	1.6	2
39	Initial Dosage Optimization of Tacrolimus in Pediatric Patients With Thalassemia Major Undergoing Hematopoietic Stem Cell Transplantation Based on Population Pharmacokinetics. <i>Annals of Pharmacotherapy</i> , <b>2021</b> , 55, 440-451	2.9	3
38	Determination of tacrolimus, three mono-demethylated metabolites and a M1 tautomer in human whole blood by liquid chromatography - tandem mass spectrometry. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , <b>2021</b> , 205, 114296	3.5	0
37	Cyclosporine and tacrolimus. <i>Topics in Companion Animal Medicine</i> , <b>1997</b> , 12, 161-6		21
36	Quality assessment issues of new immunosuppressive drugs and experimental experience. <i>Therapeutic Drug Monitoring</i> , <b>1996</b> , 18, 362-7	3.2	20
35	Evaluation of the Pro-Trac tacrolimus monoclonal whole-blood enzyme-linked immunosorbent assay for monitoring of tacrolimus levels in patients after kidney, heart, and liver transplantation. <i>Therapeutic Drug Monitoring</i> , <b>1996</b> , 18, 640-6	3.2	9
34	A simplified whole blood enzyme-linked immunosorbent assay (ProTrac II) for tacrolimus (FK506) using proteolytic extraction in place of organic solvents. <i>Therapeutic Drug Monitoring</i> , <b>1996</b> , 18, 698-705	3.2	26
33	Tacrolimus quality assessment. <i>Therapeutic Drug Monitoring</i> , <b>1997</b> , 19, 243	3.2	2
32	Measurement of tacrolimus (FK506) and its metabolites: a review of assay development and application in therapeutic drug monitoring and pharmacokinetic studies. <i>Therapeutic Drug Monitoring</i> , <b>1997</b> , 19, 338-51	3.2	46
31	A specific method for the measurement of tacrolimus in human whole blood by liquid chromatography/tandem mass spectrometry. <i>Therapeutic Drug Monitoring</i> , <b>1997</b> , 19, 470-6	3.2	35
30	Pitfalls in monitoring tacrolimus (FK 506). <i>Therapeutic Drug Monitoring</i> , <b>1997</b> , 19, 628-31	3.2	15

29	High-performance liquid chromatography-tandem mass spectrometry as a reference for analysis of tacrolimus to assess two immunoassays in patients with liver and renal transplants. <i>Therapeutic Drug Monitoring</i> , <b>1997</b> , 19, 694-700	3.2	20
28	An abbreviated area-under-the-curve monitoring for tacrolimus in patients with liver transplants. <i>Therapeutic Drug Monitoring</i> , <b>1998</b> , 20, 219-23	3.2	39
27	Successful therapy of refractory graft versus host disease with tacrolimus and Psoralen plus ultraviolet light. <i>Therapeutic Drug Monitoring</i> , <b>1998</b> , 20, 236-9	3.2	8
26	Therapeutic monitoring of tacrolimus (FK506) with the first- and second-generation microparticle enzyme immunoassays: performance and results in four patient populations. <i>Therapeutic Drug Monitoring</i> , <b>1998</b> , 20, 266-75	3.2	19
25	Therapeutic drug monitoring of tacrolimus in liver transplantation, phase III FK506 multicenter Spanish Study Group: a two-year follow-up. <i>Therapeutic Drug Monitoring</i> , <b>1998</b> , 20, 602-6	3.2	9
24	Clinical pharmacokinetics of tacrolimus in heart transplant recipients. <i>Therapeutic Drug Monitoring</i> , <b>1999</b> , 21, 2-7	3.2	25
23	Analysis of whole blood tacrolimus concentrations in liver transplant patients exhibiting impaired liver function. <i>Therapeutic Drug Monitoring</i> , <b>1999</b> , 21, 585-92	3.2	11
22	Relationship of FK506 whole blood concentrations and efficacy and toxicity after liver and kidney transplantation. <i>Transplantation</i> , <b>1996</b> , 62, 920-6	1.8	237
21	Quantitation of Tacrolimus in Human Whole Blood Samples Using the MITRA Microsampling Device. <i>Therapeutic Drug Monitoring</i> , <b>2021</b> , 43, 364-370	3.2	3
20	ABCB1 1199G>A genetic polymorphism (Rs2229109) influences the intracellular accumulation of tacrolimus in HEK293 and K562 recombinant cell lines. <i>PLoS ONE</i> , <b>2014</b> , 9, e91555	3.7	33
19	Clinical Risk Scoring Models for Prediction of Acute Kidney Injury after Living Donor Liver Transplantation: A Retrospective Observational Study. <i>PLoS ONE</i> , <b>2015</b> , 10, e0136230	3.7	51
18	Cynomolgus monkeys are successfully and persistently infected with hepatitis E virus genotype 3 (HEV-3) after long-term immunosuppressive therapy. <i>PLoS ONE</i> , <b>2017</b> , 12, e0174070	3.7	25
17	Recommendations for the Outpatient Surveillance of Renal Transplant Recipients. <i>Journal of the American Society of Nephrology: JASN</i> , <b>2000</b> , 11, S1-S86	12.7	431
16	Quantification of the Immunosuppressant Tacrolimus on Dried Blood Spots Using LC-MS/MS. <i>Journal of Visualized Experiments</i> , <b>2015</b> , e52424	1.6	11
15	Tacrolimus increases the expression level of the chemokine receptor CXCR2 to promote renal fibrosis progression. <i>International Journal of Molecular Medicine</i> , <b>2019</b> , 44, 2181-2188	4.4	4
14	Immune monitoring post liver transplant. <i>World Journal of Transplantation</i> , <b>2014</b> , 4, 30-9	2.3	30
13	Overview of extended release tacrolimus in solid organ transplantation. <i>World Journal of Transplantation</i> , <b>2016</b> , 6, 144-54	2.3	16
12	A longitudinal replicate study of immunosuppressive drugs: a College of American Pathologists study. <i>Archives of Pathology and Laboratory Medicine</i> , <b>2003</b> , 127, 283-8	5	14

11	A fast and simple high-performance liquid chromatography/mass spectrometry method for simultaneous measurement of whole blood tacrolimus and sirolimus. <i>Archives of Pathology and Laboratory Medicine</i> , <b>2005</b> , 129, 661-5	5	23
10	Pharmacologic Monitoring of Immunosuppressive Drugs. <b>2001</b> , 43-59		
9	The potential role of immunosuppressive macrocyclic lactones. <b>2001</b> , 43-75		
8	Evaluation of the Effects of Tacrolimus According to the Adjustment of Dosage Conversion Ratio in Switching from Intravenous to Oral Administration. <i>Journal of Korean Society of Health-System Pharmacists</i> , <b>2013</b> , 30, 330-342	0	
7	Using the Logistic Regression to Predict Saudi Kidney Transplant Rejection Patients. <i>Biometrics &amp; Biostatistics International Journal</i> , <b>2017</b> , 5,	0.1	
6	Population pharmacokinetics of tacrolimus in pediatric patients with systemic-onset juvenile idiopathic arthritis: Initial dosage recommendations. <i>Experimental and Therapeutic Medicine</i> , <b>2019</b> , 18, 4653-4660	2.1	1
5	Population pharmacokinetics model and initial dose optimization of tacrolimus in children and adolescents with lupus nephritis based on real-world data. <i>Experimental and Therapeutic Medicine</i> , <b>2020</b> , 20, 1423-1430	2.1	1
4	Monitoring Tacrolimus Trough Concentrations During the First Year After Kidney Transplantation: A National Retrospective Cohort Study. <i>Frontiers in Pharmacology</i> , <b>2020</b> , 11, 566638	5.6	1
3	A review on therapeutic drug monitoring of immunosuppressant drugs. <i>Iranian Journal of Basic Medical Sciences</i> , <b>2011</b> , 14, 485-98	1.8	28
2	Propofol's effect on the sciatic nerve: Harmful or protective?. <i>Neural Regeneration Research</i> , <b>2013</b> , 8, 2520-30	4.5	1
1	Cytochrome P450 oxidoreductase variant A503V contributes to the increased CYP3A5 activity with tacrolimus in vitro. 1-7		